Ability to drive, halogenated anaesthetics
The out-patients should not drive or use any tools or machines within the 24 hours after the anesthesia
Ability to drive, local anaesthetics
Transient decrease of the ability to react
ACE inhibitors, anaesthetics ---> SmPC of [enalapril] of eMC
Concomitant use of certain anaesthetic medicinal products with ACE inhibitors may result in further reduction of blood pressure
ACE inhibitors, general anesthetics
Enhanced hypotensive effect when general anaesthetics given with ACE inhibitors.
Acebutolol, anaesthetics
Acebutolol therapy should be brought to the attention of the anaesthetist prior to general anaesthesia
Acetaminophen, local anaesthetics ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Adrenaline [1], halogenated anaesthetics ---> SmPC of [1] of eMC
Volatile liquid anaesthetics such as halothane increase the risk of adrenaline-induced ventricular arrhythmias and acute pulmonary oedema if hypoxia is present.
AIIRA, general anesthetics
Enhanced hypotensive effect when general anaesthetics given with angiotensin-II receptor antagonists.
Alfa-adrenergic receptor blockers, general anesthetics
Enhanced hypotensive effect when general anaesthetics given with alpha-blockers.
Alfentanyl [1], anaesthetics ---> SmPC of [1] of eMC
Treatment with drugs which may depress the heart or increase vagal tone, such as beta-blockers and anaesthetic agents, may predispose to bradycardia or hypotension.
Alfentanyl [1], halogenated anaesthetics ---> SmPC of [1] of eMC
CNS depressants may enhance or prolong the respiratory depressant effects of alfentanil.
Alfuzosin [1], general anesthetics ---> SmPC of [1] of eMC
It could cause profound hypotension. It is recommended that alfuzosin be withdrawn 24 hours before surgery
Alprazolam [1], anaesthetics ---> SmPC of [1] of eMC
Enhancement of the central depressive effect may occur in case of concomitant use of alprazolam with other CNS depressants
Amfepramone, anaesthetics
Concomitant use of amfepramone and anesthetics may cause arrhythmias
Amfepramone, general anesthetics
Concomitant use of amfepramone and anesthetics may cause arrhythmias
Amfepramone, halogenated anaesthetics
Concomitant use of amfepramone and anesthetics may cause arrhythmias
Amikacine [1], halogenated anaesthetics ---> SmPC of [1] of eMC
The use of amikacin is not recommended in patients under the influence of anaesthetics or muscle-relaxing drugs as neuromuscular blockade and consequent respiratory depression may occur.
Amikacine, anaesthetics
The use of amikacin is not recommended in patients under the influence of anaesthetics or muscle-relaxing drugs as neuromuscular blockade and consequent respiratory depression may occur.
Aminoglycoside antibiotics, general anesthetics
Care is required when patients being treated with aminoglycosides are to receive a general anaesthetic or opioids in order to avoid the possible neuromuscular side-effects provoking severe respiratory depression.
Aminoglycoside antibiotics, halogenated anaesthetics
Halogenated anaesthetics may potentiate the neuromuscular block
Amiodarone, general anesthetics
Bradycardia unresponsive to atropine, hypotension, disturbances of conduction, decreased cardiac output.
Amisulpride [1], anaesthetics ---> SmPC of [1] of eMC
Caution is advised when coadministering amisulpride with CNS depressants
Amitriptyline [1], anaesthetics ---> SmPC of [1] of eMC
Concomitant therapy of amitriptyline and anaesthetics may increase the risk of arrhythmias and hypotension.
Anaesthetics [1], atenolol/nifedipine ---> SmPC of [1] of eMC
Caution must be exercised when using anaesthetic agents with atenolol/nifedipine. The anaesthetist should be informed and the choice of anaesthetic should be the agent with as little negative inotropic activity as possible.
Anaesthetics [1], flupentixol ---> SmPC of [1] of eMC
In common with other antipsychotics, flupentixol enhances the response to other CNS depressants.
Anaesthetics [1], procarbazine ---> SmPC of [1] of eMC
Procarbazine may enhance the effect of other central nervous system depressants
Anaesthetics, apraclonidine [2] ---> SmPC of [2] of eMC
The possibility of an additive or potentiating effect with CNS depressants should be considered.
Anaesthetics, atenolol [2] ---> SmPC of [2] of eMC
Use of beta-blockers with anaesthetic drugs may result in attenuation of the reflex tachycardia and increase the risk of hypotension. Anaesthetic agents causing myocardial depression are best avoided.
Anaesthetics, atenolol/chlortalidone [2] ---> SmPC of [2] of eMC
Use of beta-blockers with anaesthetic drugs may result in attenuation of the reflex tachycardia and increase the risk of hypotension. Anaesthetic agents causing myocardial depression are best avoided.
Anaesthetics, atracurium
The co-administration may enhance and/or prolong the neuromuscular block of atracurium
Anaesthetics, benperidol
The risk of hypotension with anaesthetics may be increased when benperidol is given concomitantly.
Anaesthetics, benzodiazepines
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Anaesthetics, betablockers ---> SmPC of [atenolol] of eMC
Use of beta-blockers with anaesthetic drugs may result in attenuation of the reflex tachycardia and increase the risk of hypotension. Anaesthetic agents causing myocardial depression are best avoided.
Anaesthetics, betaxolol
The combination of betaxolol and an anaesthetic may potentiate the hypotensive effect. The negative inotropic effect of both can be additive
Anaesthetics, bisoprolol [2] ---> SmPC of [2] of eMC
Attenuation of the reflex tachycardia and increase of the risk of hypotension
Anaesthetics, brimonidine [2] ---> SmPC of [2] of EMA
The possibility of an additive or potentiating effect with CNS depressants should be considered.
Anaesthetics, brinzolamide/brimonidine [2] ---> SmPC of [2] of EMA
Caution is advised due to the possibility of an additive or potentiating effect of brinzolamide/brimonidine with CNS depressants
Anaesthetics, bromazepam
Enhancement of the depressor effect on the central nervous system
Anaesthetics, brotizolam
The co-administration of brotizolam with other central nervous system depressants may enhance the central nervous depressant effect
Anaesthetics, captopril
The co-administration may cause hypotension
Anaesthetics, celiprolol [2] ---> SmPC of [2] of eMC
Therapy with beta-adrenoceptor blockers must be reported to the anaesthetist prior to general anaesthesia as they may attenuate the reflex tachycardia and increase the risk of hypotension
Anaesthetics, chlordiazepoxide [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if chlordiazepoxide is combined with other CNS-depressant drugs.
Anaesthetics, chlortetracycline
Chlortetracycline increases the neuromuscular blockade
Anaesthetics, cilazapril [2] ---> SmPC of [2] of eMC
Concomitant use of certain anesthetic medicinal products with ACE inhibitors may result in further reduction of blood pressure
Anaesthetics, cinnarizine
Concurrent use of cinnarizine and CNS depressants may potentiate the sedative effects
Anaesthetics, cisatracurium [2] ---> SmPC of [2] of eMC
Anaesthetics increase the magnitude and/or duration of action of non-depolarising neuromuscular blocking agents
Anaesthetics, clobazam [2] ---> SmPC of [2] of eMC
Especially when clobazam is administered at higher doses, an enhancement of the central depressive effect may occur in cases of combination with other central depressive drugs
Anaesthetics, CNS depressants
The co-administration of anesthetic agents with CNS depressants may have synergistic effects
Anaesthetics, cyclizine
Cyclizine may have additive effects with other central nervous system depressants
Anaesthetics, dantrolene
The co-administration of dantrolene and CNS depressants should be avoided due to the adverse reactions of dantrolene may be enhanced (specially the CNS depressant effect and muscle weakness)
Anaesthetics, delapril
Concomitant use of certain anaesthetic medicinal products with ACE inhibitors may result in further reduction of blood pressure
Anaesthetics, dexmedetomidine [2] ---> SmPC of [2] of EMA
Co-administration of dexmedetomidine with anaesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects, including sedative, anaesthetic and cardiorespiratory effects.
Anaesthetics, diazepam [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur
Anaesthetics, dihydralazine
The co-administration may enhance the hypotensive and hypnotic effect
Anaesthetics, diltiazem [2] ---> SmPC of [2] of eMC
Depression of cardiac contractility, conductivity and automaticity, as well as the vascular dilatation associated with anaesthetics may be potentiated by calcium channel blockers.
Anaesthetics, dimenhydrinate
Dimenhydrinate may increase the effects of other CNS depressors and enhance the sedative effects
Anaesthetics, diphenhydramine
Mutual enhancement of CNS-depressant effect
Anaesthetics, dipotassium clorazepate
The combination of CNS depressors may mutually potentiate the depressor effect on the CNS
Anaesthetics, dixyrazine
Dixyrazine enhances the effect of anaesthetic agent
Anaesthetics, doxylamine
Antihistaminic agents have additive effects with other CNS depressants
Anaesthetics, enalapril [2] ---> SmPC of [2] of eMC
Concomitant use of certain anaesthetic medicinal products with ACE inhibitors may result in further reduction of blood pressure
Anaesthetics, enalapril/hydrochlorothiazide
Increased hypotensive effect.
Anaesthetics, felodipine/ramipril [2] ---> SmPC of [2] of eMC
Potentiation of the antihypertensive effect is to be anticipated.
Anaesthetics, flurazepam [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Anaesthetics, fondaparinux
With spinal/epidural anaesthesia or spinal puncture cannot be excluded epidural or spinal haematomas that may cause long-term or permanent paralysis
Anaesthetics, formoterol/glycopyrronium/budesonide [2] ---> SmPC of [2] of EMA
There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons.
Anaesthetics, fosinopril [2] ---> SmPC of [2] of eMC
Concomitant use of certain anaesthetic medicinal products with ACE inhibitors may result in further reduction of blood pressure
Anaesthetics, hydrochlorothiazide
Increased hypotensive effect.
Anaesthetics, hydrocodone
The co-administration of hydrocodone and other CNS depressants may enhance the sedative and respiratory depressor effects
Anaesthetics, irreversible non-selective MAO-inhibitors
About interactions of irreversible MAO inhibitors (e. g. tranylcypromine) with anaesthetics, which in some cases were severe (unstable circulation, comatose states)
Anaesthetics, levobunolol
The co-administration may attenuate compensatory tachycardia and increase the risk of hypotension
Anaesthetics, levodopa
The concomitant use may induce arrhythmias
Anaesthetics, levomepromazine
The co-administration of levomepromazine with other central nervous depressants will cause a greater depressant effect on central nervous system
Anaesthetics, levomethadone
Enhancement of effects and adverse effects, particularly respiratory depression
Anaesthetics, lisinopril [2] ---> SmPC of [2] of eMC
Concomitant use of certain anaesthetic medicinal products with ACE inhibitors may result in further reduction of blood pressure
Anaesthetics, loprazolam [2] ---> SmPC of [2] of eMC
Combination with CNS depressants causes enhancement of the central depressive effects of loprazolam.
Anaesthetics, lorazepam [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if lorazepam is combined with other CNS depressants
Anaesthetics, lormetazepam
The benzodiazepines, including lormetazepam produce additive CNS depressant effects when co-administered with other medications which themselves produce CNS depression
Anaesthetics, medazepam
The co-administration of medazepam with other central nervous system depressants may enhance the central nervous depressant effect.
Anaesthetics, melperone
An enhancement of the central depressive effect may occur in cases of combination of melperone with other central depressive drugs
Anaesthetics, methocarbamol
Methocarbamol may potentiate the effects of other central nervous system depressants and stimulants
Anaesthetics, methyldopa
As concomitant use may enhance the hypotensive effect, patients may require reduced doses of anaesthetics when on methyldopa.
Anaesthetics, methylergometrine
The anesthetic agent may decrease the uterotonic effect of methylergometrine
Anaesthetics, metipranolol
Enhancement of cardiodepressant effect
Anaesthetics, metolazone
The co-administration may enhance the risk of orthostatic hypotension
Anaesthetics, minoxidil
Additive effect
Anaesthetics, muscle relaxants (non-depolarizing) ---> SmPC of [cisatracurium] of eMC
Anaesthetics increase the magnitude and/or duration of action of non-depolarising neuromuscular blocking agents
Anaesthetics, naphazoline
Enhancement of the cardiovascular effects of sympathomimetic agent
Anaesthetics, netilmicin
Possible increase of neuromuscular blockade
Anaesthetics, nitrazepam
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Anaesthetics, nitroprussiate
Enhanced blood pressure lowering
Anaesthetics, opipramol
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
Anaesthetics, oxazepam
Enhancement of other CNS depressant drugs
Anaesthetics, oxomemazine
Enhancement of CNS depressant effect
Anaesthetics, oxycodone [2] ---> SmPC of [2] of eMC
Central nervous system depressants can enhance the adverse reactions of oxycodone, in particular respiratory depression.
Anaesthetics, penbutolol
Anaesthetics may potentiate the effect of penbutolol, what can cause hypotension
Anaesthetics, perindopril [2] ---> SmPC of [2] of eMC
Concomitant use of certain anaesthetic medicinal products with ACE inhibitors may result in further reduction of blood pressure
Anaesthetics, perphenazine
Risk of sedation and/or toxicity when perphenazine is administered with CNS depressants
Anaesthetics, phenothiazines
Phenothiazine may enhance the effect of other CNS depressants
Anaesthetics, pindolol/clopamide
Concomitant use of pindolol/clopamide and anesthetic agents may enhance the negative inotropic effect and also may cause a pronounced hypotension
Anaesthetics, polidocanol
If polidocanol is combined with other anesthetists, there is the risk of additive effect on the cardiovascular system
Anaesthetics, promazine
The concomitant administration of promazine with central nervous system depressants (including alcohol and anaesthetics) may result in accentuation of their effects
Anaesthetics, propranolol [2] ---> SmPC of [2] of eMC
Care should be taken when using anaesthetic agents with propranolol. The anaesthetist should be informed and the choice of anaesthetic should be the agent with as little negative inotropic activity as possible.
Anaesthetics, quazepam
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
Anaesthetics, quinapril [2] ---> SmPC of [2] of eMC
Angiotensin converting enzyme inhibitors have been shown to block angiotensin II formation secondary to compensatory renin release. This may lead to hypotension
Anaesthetics, ramipril [2] ---> SmPC of [2] of eMC
Potentiation of the risk of hypotension is to be anticipated. Caution is recommended
Anaesthetics, retigabine [2] ---> SmPC of [2] of EMA
Trobalt may increase the duration of anaesthesia induced by some anaesthetics (for example thiopental sodium)
Anaesthetics, ritodrine
Strong anesthetics may enhance the cardiovascular effects of intravenous ritodrine, specially arrhytmias or hypotension
Anaesthetics, scopolamine
The previous administration of an anaesthetic agent enhances the mydriatic and cycloplegic effects of scopolamine
Anaesthetics, spirapril
Increased hypotensive effect.
Anaesthetics, sympathomimetics
Enhancement of the cardiovascular effects of sympathomimetic agent
Anaesthetics, temazepam
Enhancement of the central depressive effect may occur if temazepam is combined with anaesthetics
Anaesthetics, thiethylperazine
The co-administration may potentiate the CNS depressant effect
Anaesthetics, thioridazine
Phenothiazine may enhance the effect of other CNS depressants
Anaesthetics, timolol [2] ---> SmPC of [2] of eMC
Concomitant use of beta blockers and anaesthetics may attenuate reflex tachycardia and increase the risk of hypotension.
Anaesthetics, tramazoline
Enhancement of the cardiovascular effects of sympathomimetic agent
Anaesthetics, trandolapril/verapamil [2] ---> SmPC of [2] of eMC
Trandolapril/verapamil may enhance the hypotensive effects of certain anaesthetic medicinal products.
Anaesthetics, tranylcypromine
About interactions of irreversible MAO inhibitors (e. g. tranylcypromine) with anaesthetics, which in some cases were severe (unstable circulation, comatose states)
Anaesthetics, triazolam
Increased CNS depressant effect with the co-administration of triazolam and anesthetics may occur
Anaesthetics, tricyclic antidepressant
The co-administration may cause a mutual potentiation of the depressor effect on the CNS. Anaesthetics given during tricyclic antidepressant therapy may increase the risk of arrhythmias and hypotension
Anaesthetics, trifluoperazine [2] ---> SmPC of [2] of eMC
Potentiation may occur if antipsychotic drugs are combined with CNS depressants
Anaesthetics, vancomycin [2] ---> SmPC of [2] of eMC
The combination may increase the frequency of adverse effects. These may be minimized by the vancomycin administration as a 60-minute infusion prior to anaesthetic induction
Anaesthetics, zaleplon [2] ---> SmPC of [2] of EMA
Combination of zaleplon with other CNS-acting compounds may enhance the central sedation
Anaesthetics, zofenopril
ACE inhibitors may enhance the hypotensive effects of certain anaesthetic medicinal products.
Anaesthetics, zolpidem [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur in case of concomitant use of zolpidem with other central nervous system depressants
Anaesthetics, zopiclone [2] ---> SmPC of [2] of eMC
The combination with CNS depressants an enhancement of the central depressive effect may occur.
Antiadrenergics, general anesthetics
Enhanced hypotensive effect when general anaesthetics given with adrenergic neurone blockers.
Articaine, local anaesthetics ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Articaine/epinephrine, local anaesthetics
The combination of local anaesthetics has additive effects on CNS and cardiovascular system
Atracurium [1], halogenated anaesthetics ---> SmPC of [1] of eMC
The neuromuscular block produced by atracurium besilate may be increased by the concomitant use of inhalational anaesthetics
Baclofen, general anesthetics
Concomitant use of intrathecal baclofen and general anaesthetic agents (e. g. fentanyl, propofol) may increase the risk of cardiac disorders and convulsions
Bambuterol, halogenated anaesthetics
The co-administration may increase the risk of arrhythmias
Benzocaine, local anaesthetics ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Benzodiazepines, halogenated anaesthetics
Benzodiazepines are expected to decrease the MAC of inhalational anaesthetics.
Betablockers, general anesthetics ---> SmPC of [atenolol] of eMC
Use of beta-blockers with anaesthetic drugs may result in attenuation of the reflex tachycardia and increase the risk of hypotension. Anaesthetic agents causing myocardial depression are best avoided.
Betablockers, halogenated anaesthetics ---> SmPC of [propranolol] of eMC
Concomitant use of beta-adrenergic antagonists and anaesthetics may attenuate reflex tachycardia and increase the risk of hypotension. Sudden withdrawal of beta-blocker treatment should be avoided if possible.
Budesonide/formoterol [1], halogenated anaesthetics ---> SmPC of [1] of EMA
There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons and formoterol.
Bupivacaine, local anaesthetics [2] ---> SmPC of [2] of eMC
The combination of local anaesthetics has additive effects on CNS and cardiovascular system
Bupivacaine/meloxicam [1], local anaesthetics ---> SmPC of [1] of EMA
Bupivacaine should be used with caution in patients receiving other local anaesthetics or active substances structurally related to amide-type local anaesthetics, since the systemic toxic effects are additive
Calcium antagonists, general anesthetics [2] ---> SmPC of [2] of eMC
Depression of cardiac contractility, conductivity and automaticity, as well as the vascular dilatation associated with anaesthetics may be potentiated by calcium channel blockers.
Calcium antagonists, halogenated anaesthetics ---> SmPC of [verapamil] of eMC
Caution should be exercised when calcium antagonists are used concomitantly with inhalation anaesthetics due to the risk of additive negative inotropic effect.
Carbetocin [1], halogenated anaesthetics ---> SmPC of [1] of eMC
Some inhalation-anesthetics, such as halothane and cyclopropane may enhance the hypotensive effect and weaken the effect of carbetocin on the uterus. Arrhythmias have been reported for oxytocin during concomitant use.
Carteolol, halogenated anaesthetics
Betablockers reduce the compensatory cardiovascular reactions
Carvedilol [1], halogenated anaesthetics ---> SmPC of [1] of eMC
Caution is advised in case of anaesthesia due to synergistic, negative inotrope and hypotensive effect of carvedilol and certain anaesthetics.
Chloroquine, local anaesthetics ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Clenbuterol, halogenated anaesthetics
The co-administration may increase the risk of arrhythmias
Clobenzorex, general anesthetics
The co-administration may cause arrhytmias
Clomipramine [1], general anesthetics ---> SmPC of [1] of eMC
Tricyclic antidepressants may potentiate the effects of other central depressant substances
Colistimethate, halogenated anaesthetics
Pay attention to neurotoxic reactions
Cyclophosphamide, local anaesthetics ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Dapsone, local anaesthetics
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Diazepam [1], general anesthetics ---> SmPC of [1] of eMC
Enhancement of the central depressive effect may occur
Dipivefrine, halogenated anaesthetics
Increased risk of ventricular fibrillation
Dopamine [1], halogenated anaesthetics ---> SmPC of [1] of eMC
The myocardium is sensitised by the effect of dopamine, cyclopropane or halogenated hydrocarbon anaesthetics, and these should be avoided. This interaction applies both to pressor activity and cardiac beta adrenergic stimulation.
Doubutamine [1], halogenated anaesthetics ---> SmPC of [1] of eMC
Although it is less likely than adrenaline to produce ventricular arrhythmias, dobutamine should be used with extreme caution during anaesthesia halothane and other halogenated anaesthetics.
Doxepin, general anesthetics
General anaesthetics and local anaesthetics given during tricyclic or tetracyclic anti-depressant therapy may increase the risk of arrhythmias and hypotension, or hypertension.
Ephedrine [1], halogenated anaesthetics ---> SmPC of [1] of eMC
Halogenated volatile anaesthetics with ephedrine: Risk of peri-operative hypertensive crisis.
Epinephrine [1], halogenated anaesthetics ---> SmPC of [1] of eMC
Volatile liquid anaesthetics such as halothane increase the risk of adrenaline-induced ventricular arrhythmias and acute pulmonary oedema if hypoxia is present.
Ergometrine, general anesthetics
The co-administration may enhance the peripheral vasoconstriction
Ergonovine, general anesthetics
The co-administration may enhance the peripheral vasoconstriction
Esketamine, halogenated anaesthetics
Enhancement of anesthetic effect
Esmolol [1], halogenated anaesthetics ---> SmPC of [1] of eMC
The hypotensive effects of inhalation anaesthetic agents may be increased in the presence of esmolol.
Etilefrine, halogenated anaesthetics
The co-administration may enhance the sympathicomimetic effect on the cardiac muscle and cause heart rhythm disorders
Felodipine/metoprolol, halogenated anaesthetics
In patients receiving beta-blocker therapy, inhalation anaesthetics enhance the cardiodepressant effect
Fenoterol, halogenated anaesthetics
Increased risk of heart rhythm disorders and decreased blood pressure.
Fentanyl [1], general anesthetics ---> SmPC of [1] of EMA
The concomitant use of fentanyl with other central nervous system depressants may produce additive depressant effects.
Fluphenazine [1], general anesthetics ---> SmPC of [1] of eMC
Phenothiazines may increase the central nervous system depression produced by other CNS depressants
Flutamide, local anaesthetics ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Formoterol, halogenated anaesthetics ---> SmPC of [budesonide/formoterol] of EMA
There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons and formoterol.
Furosemide, general anesthetics
The co-administration may enhance the hypotensive effect
Gallopamil, halogenated anaesthetics
Mutual enhancement of cardiovascular effects.
General anesthetics [1], lofepramine ---> SmPC of [1] of eMC
Effects of lofepramine may be potentiated when administered with CNS depressant substances. Anaesthetics given during tricyclic antidepressant therapy may increase the risk of arrhythmias and hypotension.
General anesthetics [1], tricyclic antidepressant ---> SmPC of [1] of eMC
General anaesthetics and local anaesthetics given during tricyclic or tetracyclic anti-depressant therapy may increase the risk of arrhythmias and hypotension, or hypertension.
General anesthetics, hydromorphone [2] ---> SmPC of [2] of eMC
Centrally acting drugs may interact with hydromorphone and potentiate the effects of either drug, e.g. sedation, respiratory depression
General anesthetics, imipramine [2] ---> SmPC of [2] of eMC
Tricyclic antidepressants may potentiate the CNS depressant effects of central depressant drugs
General anesthetics, labetalol [2] ---> SmPC of [2] of eMC
Use of beta-blockers with anaesthetic drugs may result in attenuation of the reflex tachycardia and increase the risk of hypotension. Anaesthetic agents causing myocardial depression are best avoided.
General anesthetics, melitracen
The antidepressant may potentiate the effects of other central depressant substances and increase the risk of arrhytmia and hypertension
General anesthetics, methadone [2] ---> SmPC of [2] of eMC
The depressant effects of methadone are likely to be enhanced by depressants of the CNS. As well as CNS depression, there may be respiratory depression and/or hypotension.
General anesthetics, morphine [2] ---> SmPC of [2] of eMC
Morphine sulphate potentiates the effects of other central nervous depressants
General anesthetics, nadolol [2] ---> SmPC of [2] of eMC
General anaesthetics that cause myocardial depression should be avoided as the patient may be subject to protracted severe hypotension.
General anesthetics, neomycin
Care is required when patients being treated with aminoglycosides are to receive a general anaesthetic or opioids in order to avoid the possible neuromuscular side-effects provoking severe respiratory depression.
General anesthetics, nortriptyline [2] ---> SmPC of [2] of eMC
Anaesthetics given during tricyclic antidepressant therapy may increase the risk of arrhythmias and hypotension
General anesthetics, opipramol
The antidepressant may potentiate the effects of other central depressant substances
General anesthetics, oxytocin [2] ---> SmPC of [2] of eMC
Inhalation anaesthetics have a relaxing effect on the uterus and produce a notable inhibition of uterine tone and thereby, may diminish the uterotonic effect of oxytocin.
General anesthetics, phentermine
The co-administration is contraindicated
General anesthetics, ritodrine
Strong anesthetics may enhance the cardiovascular effects of intravenous ritodrine, specially arrhytmias or hypotension
General anesthetics, ropivacaine [2] ---> SmPC of [2] of eMC
Simultaneous use of ropivacaine with general anaesthetics may potentiate each others (adverse) effects
General anesthetics, sufentanil
The co-administration may enhance the respiratory depressor effect of sufentanil
General anesthetics, talinolol
Pronounced hypotension. The negative inotrope effects of both substances may be additive
General anesthetics, tetracyclic antidepressant
General anaesthetics and local anaesthetics given during tricyclic or tetracyclic anti-depressant therapy may increase the risk of arrhythmias and hypotension, or hypertension.
General anesthetics, triamterene [2] ---> SmPC of [2] of eMC
The co-administration of triamterene and general anaesthetics may enhance the hypotensive effect
General anesthetics, zuclopenthixol [2] ---> SmPC of [2] of eMC
Zuclopenthixol may potentiate the effects of general anaesthetics
Gentamicin, halogenated anaesthetics
Halogenated anaesthetics may potentiate the neuromuscular blockade
Halogenated anaesthetics, isoniazid [2] ---> SmPC of [2] of eMC
General anaesthetics possibly potentiate hepatotoxicity of isoniazid
Halogenated anaesthetics, isoprenaline
Isoprenaline should be used with caution in patients receiving inhalation anesthetics or cyclopropane, due to arrythmias may occur
Halogenated anaesthetics, ketamine [2] ---> SmPC of [2] of eMC
The use of halogenated anaesthetics concomitantly with ketamine can lengthen the elimination half-life of ketamine and delay recovery from anaesthesia.
Halogenated anaesthetics, methylphenidate [2] ---> SmPC of [2] of eMC
With halogenated anaesthetics there is a risk of sudden blood pressure increase during surgery. If surgery is planned, methylphenidate treatment should not be used on the day of surgery.
Halogenated anaesthetics, metoprolol
In patients receiving beta-blocker therapy, inhalation anaesthetics enhance the cardiodepressant effect
Halogenated anaesthetics, midazolam [2] ---> SmPC of [2] of EMA
Midazolam decreases the minimum alveolar concentration of inhalation anaesthetics.
Halogenated anaesthetics, mivacurium [2] ---> SmPC of [2] of eMC
The neuromuscular block produced by mivacurium may be increased by the concomitant use of inhalational anaesthetics
Halogenated anaesthetics, nebivolol [2] ---> SmPC of [2] of eMC
Concomitant use of beta-adrenergic antagonists and anaesthetics may attenuate reflex tachycardia and increase the risk of hypotension. Sudden withdrawal of beta-blocker treatment should be avoided if possible.
Halogenated anaesthetics, nitrous oxide
Additive effect on the CNS. It should be taken into account the pronounced sedative risk and depression of the protective reflexes
Halogenated anaesthetics, noradrenaline [2] ---> SmPC of [2] of eMC
The use of noradrenaline with volatile halogenated anaesthetic agents is not recommended because severe, prolonged hypertension and possible arrhythmias may result
Halogenated anaesthetics, norepinephrine [2] ---> SmPC of [2] of eMC
The use of noradrenaline with volatile halogenated anaesthetic agents is not recommended because severe, prolonged hypertension and possible arrhythmias may result
Halogenated anaesthetics, opiate agonists
The combination may decrease the minimal alveolar concentration of halogenated anaesthetic agent and enhance or prolong the respiratory depressant effect of opioid
Halogenated anaesthetics, orciprenaline
Halogenated anaesthetics sensitize the myocard to sympathomimetic agents which is associated with the risk of rhythm disorders and probably until ventricular fibrillation
Halogenated anaesthetics, oxprenolol [2] ---> SmPC of [2] of eMC
Beta-blockers and certain anaesthetics (e.g. halothane) are additive in their cardiodepressant effect. However, continuation of beta-blockers reduces the risk of arrhythmia during anaesthesia
Halogenated anaesthetics, pancuronium
Possible enhancement of neuromuscular blocking effects of pancuronium
Halogenated anaesthetics, phenylephrine [2] ---> SmPC of [2] of eMC
Phenylephrine may interact with halogenated inhalational anaesthetics, to induce ventricular fibrillation.
Halogenated anaesthetics, phenylephrine/ketorolac [2] ---> SmPC of [2] of EMA
Phenylephrine may potentiate the cardiovascular depressant effects of some inhalation anesthetic medicinal products.
Halogenated anaesthetics, piritramide
The co-administration may enhance the adverse effects of piritramide, particularly respiratory depression
Halogenated anaesthetics, propofol
The co-administration may enhance the anesthetic effect of propofol, prolong the anesthesia duration and decrease the respiratory rate
Halogenated anaesthetics, propranolol [2] ---> SmPC of [2] of EMA
Halogenated anesthetic agents may depress myocardial contractility and vascular compensating response when administered with propranolol.
Halogenated anaesthetics, pseudoephedrine [2] ---> SmPC of [2] of eMC
There may be increased risk of arrhythmias if pseudoephedrine is given to patients receiving volatile anaesthetics
Halogenated anaesthetics, remifentanil [2] ---> SmPC of [2] of eMC
As with other opioids remifentanil decreases the amounts or doses of inhaled and IV anaesthetics required for anaesthesia
Halogenated anaesthetics, reproterol
The co-administration of halogenated anaesthetics in patients treated with reproterol may increase the risk of severe heart rhythm disorders
Halogenated anaesthetics, ritodrine
Strong anesthetics may enhance the cardiovascular effects of intravenous ritodrine, specially arrhytmias or hypotension
Halogenated anaesthetics, rocuronium [2] ---> SmPC of [2] of eMC
Halogenated volatile anaesthetics potentiate the neuromuscular block of rocuronium. The effect only becomes apparent with maintenance dosing
Halogenated anaesthetics, salbutamol [2] ---> SmPC of [2] of eMC
Owing to the additional antihypertensive effect, there is increased uterine inertia with haemorrhage risk; in addition, serious ventricular rhythm disorders due to increased cardiac reactivity have been reported with halogenated anaesthetics.
Halogenated anaesthetics, sotalol
Sotalol decreases the cardiovascular compensation mechanisms
Halogenated anaesthetics, St. John's wort ---> SmPC of [sevoflurane] of eMC
Severe hypotension and delayed emergence from anaesthesia with halogenated inhalational anaesthetics have been reported in patients treated long-term with St John's Wort.
Halogenated anaesthetics, succinylcholine ---> SmPC of [suxamethonium] of eMC
Enhancement or prolongation of the neuromuscular effects of suxamethonium by mechanisms unrelated to plasma cholinesterase activity.
Halogenated anaesthetics, sufentanil [2] ---> SmPC of [2] of EMA
The concomitant use of CNS depressants including barbiturates, benzodiazepines, neuroleptics or other opioids, halogen gases or other non-selective CNS depressants (e.g. alcohol) may enhance respiratory depression.
Halogenated anaesthetics, suxamethonium [2] ---> SmPC of [2] of eMC
Enhancement or prolongation of the neuromuscular effects of suxamethonium by mechanisms unrelated to plasma cholinesterase activity.
Halogenated anaesthetics, sympathomimetics
Halogenated anaesthetics sensitize the myocard to sympathomimetic agents which is associated with the risk of rhythm disorders and probably until ventricular fibrillation
Halogenated anaesthetics, terbutaline
The co-administration may increase the risk of arrythmias
Halogenated anaesthetics, trandolapril/verapamil [2] ---> SmPC of [2] of eMC
The concurrent use of verapamil and cardiodepressives, i.e., medicinal products that inhibit cardiac impulse generation and conduction, may produce undesirable additive effects
Halogenated anaesthetics, trazodone [2] ---> SmPC of [2] of eMC
Trazodone may enhance the effects of volatile anaesthetics, and caution should be exercised in such instances.
Halogenated anaesthetics, vecuronium [2] ---> SmPC of [2] of eMC
Halogenated volatile anaesthetics potentiate the neuromuscular block of vecuronium. The effect only becomes apparent with maintenance dosing
Halogenated anaesthetics, verapamil [2] ---> SmPC of [2] of eMC
The combination of inhaled anaesthetics with verapamil may lead to additive cardiovascular effects (e.g. AV block, bradycardia, hypotension, heart failure).
Hydroxyurea, local anaesthetics ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Isocarboxazid, local anaesthetics
Concurrent administration of isocarboxazid with local anaesthetics may lead to potentiation of their effects.
Lidocaine, local anaesthetics [2] ---> SmPC of [2] of eMC
Lidocaine should be used with caution in patients receiving other local anaesthetics since the systemic toxic effects are additive.
Lidocaine/prilocaine [1], local anaesthetics ---> SmPC of [1] of EMA
The risk of additional systemic toxicity should be considered when large doses of lidocaine/prilocaine are applied to patients already using other local anaesthetics or structurally related medicinal products
Liposomal bupivacaine [1], local anaesthetics ---> SmPC of [1] of EMA
EXPAREL liposomal should be used with caution in patients receiving other local anaesthetics or active substances structurally related to amide-type local anaesthetics, such as lidocaine and mexiletine, since the systemic toxic effects are additive.
Local anaesthetics, local anaesthetics
The combination of local anaesthetics has additive effects on CNS and cardiovascular system
Local anaesthetics, mepivacaine
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, methemoglobin reductase inhibitors
The methemoglobin reductase inhibition may increase the formation of methemoglobin
Local anaesthetics, metoclopramide ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, neostigmine
The co-administration may inhibit the effect of neostigmine on skeletal muscle
Local anaesthetics, nitric oxide ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, nitrofurantoin ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, nitroglycerine ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, nitroprussiate ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, nitrous oxide ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, noradrenaline
The co-administration of noradrenaline with local anaesthetic agents may cause a mutual potentiation of effects
Local anaesthetics, norepinephrine
The co-administration of noradrenaline with local anaesthetic agents may cause a mutual potentiation of effects
Local anaesthetics, organic nitrates ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, para-aminosalicylic acid ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, phenelzine [2] ---> SmPC of [2] of eMC
Phenelzine may potentiate the action of local anaesthetics
Local anaesthetics, phenobarbital ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, phenytoin ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, prilocaine
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, primaquine ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, procaine ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, propafenone [2] ---> SmPC of [2] of eMC
The effects of propafenone may be potentiated if it is given in combination with other local anaesthetic type agents
Local anaesthetics, pyridostigmine
The co-administration may increase the plasma levels of local anaesthetic agent and cause systemic effects
Local anaesthetics, quinine ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, rasburicase ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, rocuronium [2] ---> SmPC of [2] of eMC
Increased rocuronium effects
Local anaesthetics, ropivacaine [2] ---> SmPC of [2] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, sedatives
Caution is recommended with sedatives, which may also influence the CNS function and change the toxic effect of local anaesthetic agent
Local anaesthetics, sodium valproate ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, sulfamethoxazol
Decreased effect of sulphonamide
Local anaesthetics, sulfasalazine ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, sulphonamides ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, tetracaine ---> SmPC of [liposomal bupivacaine] of EMA
Patients that are administered local anaesthetics may be at increased risk of developing methaemoglobinamia when concurrently exposed to these oxidizing medicinal products
Local anaesthetics, vasoconstrictors ---> SmPC of [bupivacaine] of eMC
The co-administration of local anesthetics with vasoconstrictor agents prolongs the duration of action and reduces plasma levels of local anesthetic